entertainment -WSS

entertainment

author：knowledge 2025-09-06 05:14:46 - browse：2

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： STAT Summit: GSK CEO on pharma giant's new direction

hotspot

WSS

STAT Summit: GSK CEO on pharma giant's new direction

Hospital price transparency does save money, advocate argues

Study points to new risk in gene therapy death of Terry Horgan

New oral drug delivery patch is modeled after octopus tentacles

2023 Nobel Prize in Medicine goes to Karikó and Weissman

CRISPR base editing slashes cholesterol levels in monkeys

focus

entertainment

focus

Medical leaders decry Supreme Court decision on affirmative action

First Opinion Podcast: Long Covid needs a new approach

DIEP, the 'gold standard' of breast reconstruction, is under threat

How climate

Alkermes shareholders re

6 solutions to address cancer drug shortages and others

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Researchers explore possible ties between long Covid, menopause

Affirmative action in medical school literally saved lives

RSV injection headlines need to be accurate for good uptake

entertainment

European officials brace for rough respiratory virus season

STAT Summit: How a Chicago ER doctor tackles gun violence

Eli Lilly expects to double planned employment in Boston center

RSV injection headlines need to be accurate for good uptake

IVG is promising — but it won’t replace IVF quite yet

Studies point to risks of excluding people with obesity from drug trials

focus

explore

hotspot

Wikipedia